‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
A phase III clinical trial has shown that a personalized mRNA vaccine, intismeran, significantly reduces the risk of melanoma recurrence or death when combined with immunotherapy. The study, involving over 1,100 patients, suggests a major shift in personalized cancer treatment.
Why it matters
This breakthrough represents a foundational change in oncology, potentially offering a more effective, tailored approach to preventing cancer relapse.
Medical director of the Melanoma Institute Australia, Prof Georgina Long, says the research will allow scientists to harness our immune systems in more personalised ways. Photograph: Tim Bauer Medical director of the Melanoma Institute Australia, Prof Georgina Long, says the research will allow scientists to harness our immune systems in more personalised ways. Photograph: Tim Bauer Vaccines and immunisation ‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised way
Get our new political email , free app or daily news podcast
Prefer the Guardian on Google A personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or death within two years, new clinical trial results show.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in